O2matic’s Proprietary Technology to be Evaluated by the University of Colorado, Funded by the U.S. Department of Defense
21 Mayo 2024 - 11:30AM
Business Wire
O2matic, a Danish medical device company focused on developing
next-generation oxygen therapy and monitoring technologies, has
announced that its proprietary technology is the subject of
research led by Adit Ginde, MD, Professor of Emergency Medicine and
Anesthesiology at the University of Colorado School of
Medicine.
Dr. Ginde and his team’s work has paved the way for the SAVE-O2
trial, a multicenter randomized clinical trial funded by the U.S.
Department of Defense. The SAVE-O2 trial focuses on redefining
oxygen requirements in critically ill trauma patients through
targeting normoxemia.
Preliminary results from analyzing data from approximately
12,000 randomized patients have unveiled promising outcomes.
Manually targeting normoxemia successfully reduces hyperoxemia
without increasing hypoxemia, resulting in lower mortality rates,
shortened hospital stays, and decreased supplemental oxygen
requirements.
Dr. Ginde presented initial results at the Military Health
System Research Symposium in 2023, earning his team the
distinguished recognition of Outstanding Research Accomplishment.
Their advancements in oxygen therapy protocols have already begun
to influence guidelines, with updates to 10 relevant Joint Trauma
System guidelines.
Dr. Ginde and his team are now evaluating the efficacy of
automatic oxygen therapy technology, with O2matic’s proprietary
technology chosen for a multi-center study involving 300 patients.
This study, named SAVE-O2 AI, and initiated in May 2024, aims to
publish results by early 2026.
“We at O2matic are deeply honored to be part of this significant
study and eagerly anticipate the potential impact of our technology
on acute and trauma patients,” said Arnt Lund, O2matic’s CEO. “We
are also grateful to the IDE sponsor for this study, IDTS Medical,
Inc. and its CEO, Mario Nozzarella, who guided us through the U.S.
Food and Drug Administration Investigational Device Exemption (US
FDA IDE) process and received our final (non-conditional) letter
regarding the submission G230325/A001 with a strong sense of
urgency.”
The award is funded by the U.S. Department of Defense through
the Medical Technology Enterprise Consortium (MTEC) to further
oxygen research using autonomous solutions.
Disclaimer Note:
The views and conclusions contained herein are those of the
authors and should not be interpreted as necessarily representing
the official policies or endorsements, either expressed or implied,
of the U.S. Government.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521039036/en/
Media Contact: Paul Williams, MediaLine Communications,
paul@medialinecommunications.com, 310/569-0023
Study Contacts: Adit Ginde, MD, MPH, (Principal
Investigator), University of Colorado,
adit.ginde@cuanschutz.edu
Farzad Saber, Chief Business Development Officer, O2matic,
fas@O2matic.com
Anja Rode Lave, Global Product Manager, O2matic,
aro@o2matic.com
Mario Nozzarella, (Clinical Trial Sponsor), Chief Executive
Officer, IDTS Medical, Inc, mario.nozzarella@idtsmedical.com